Abstract:Abstract Background Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease whose pathophysiology involves the interplay between genetic and environmental factors, ultimately leading to dysfunction of the epidermis. While several treatments are effective in symptom management, many existing therapies offer only temporary relief and often come with side effects. For this reason, the formulation of an effective therapeutic plan is challenging and there is a need for more effective and targeted treatments that address the root causes of the condition. Here, we hypothesise that modelling the complexity of the molecular buildup of the atopic dermatitis can be a concrete means to drive drug discovery. Methods We preprocessed, harmonised and integrated publicly available transcriptomics datasets of lesional and non-lesional skin from AD patients. We inferred co-expression network models of both AD lesional and non-lesional skin and exploited their interactional properties by integrating them with a priori knowledge in order to extrapolate a robust AD disease module. Pharmacophore-based virtual screening was then utilised to build a tailored library of compounds potentially active for AD. Results In this study, we identified a core disease module for AD, pinpointing known and unknown molecular determinants underlying the skin lesions. We identified skin- and immune-cell type signatures expressed by the disease module, and characterised the impaired cellular functions underlying the complex phenotype of atopic dermatitis. Therefore, by investigating the connectivity of genes belonging to the AD module, we prioritised novel putative biomarkers of the disease. Finally, we defined a tailored compound library by characterising the therapeutic potential of drugs targeting genes within the disease module to facilitate and tailor future drug discovery efforts towards novel pharmacological strategies for AD. Conclusions Overall, our study reveals a core disease module providing unprecedented information about genetic, transcriptional and pharmacological relationships that foster drug discovery in atopic dermatitis.

Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions

Identification of Candidate Genes in Atopic Dermatitis Based on Bioinformatic Methods

Multi-Omics Research Strategies for Psoriasis and Atopic Dermatitis

Understanding Atopic Dermatitis in Asian and European Population Cohorts Using Complementary Omics Techniques

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis

Integrative network analysis suggests prioritised drugs for atopic dermatitis

Recent Advancements in the Atopic Dermatitis Mechanism

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

Multi-Ancestry Genome-Wide Association Meta-Analysis Identifies Novel Loci in Atopic Dermatitis

Molecular Biology of Atopic Dermatitis

Integrative transcriptome-wide analysis of atopic dermatitis for drug repositioning

Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives

Cellular and molecular mechanisms in atopic dermatitis

Genetics in Atopic Dermatitis: Historical Perspective and Future Prospects

Transcriptomics in atopic dermatitis

Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling

Deciphering epigenetic regulations in the inflammatory pathways of atopic dermatitis

Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

From Gut to Skin: Exploring the Potential of Natural Products Targeting Microorganisms for Atopic Dermatitis Treatment